一种Nrf2激活剂TPNA10168通过调节MAPK和NF-κB通路来减轻微质中LPS诱导的炎症
Yasuhiko Izumi1, Eri Koide1, Fumika Kobayashi1
1Laboratory of Pharmacology, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe, 658-8558, Japan.
Journal of pharmacological sciences
|July 26, 2025
概括
通过抑制关键信号通路,TPNA10168可以减少初级微质细胞的炎症. 这种化合物显示出治疗神经炎症的前景,即使没有激活Nrf2通路.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 核因子红色素2相关因子2 (Nrf2) -抗氧化反应元素 (ARE) 途径保护细胞免受氧化应激.
- Nrf2激活剂通常具有抗炎性质.
- 此前TPNA10168在BV-2微质细胞中表现出Nrf2独立的抗炎作用.
研究的目的:
- 研究TPNA10168对初级微质细胞的抗炎作用.
- 为了确定TPNA10168的抗炎作用是否在初级微质中依赖Nrf2.
主要方法:
- 主要微质细胞被用脂聚糖化物 (LPS) 和TPNA10168.8治疗.
- 进行了Nrf2敲击,以评估途径依赖性.
- 测量了炎症性基因表达 (TNF-α,IL-1β,IL-6).
- 通过酸化和转位分析信号通路激活 (ERK,p38 MAPK,NF-κB).
主要成果:
- TPNA10168显著抑制了LPS诱导的原发性微质中的炎症基因表达.
- 这些抗炎作用甚至在Nrf2敲击下也被观察到.
- TPNA10168抑制了LPS诱导的ERK,p38 MAPK和NF-κB p65.5的酸化.
- 核转移NF-κB没有受到TPNA10168.8的影响.
结论:
- TPNA10168有效地减弱了微质激活和神经炎症.
- 它的抗炎作用通过对关键信号通路的Nrf2独立抑制来介导.
- TPNA10168是神经炎症疾病的潜在治疗候选者.
更多相关视频
09:04Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
Published on: May 22, 2014
21.0K
10:57NF-κB-dependent Luciferase Activation and Quantification of Gene Expression in Salmonella Infected Tissue Culture Cells
Published on: January 12, 2020
10.7K
相关概念视频
NF-κB-dependent Signaling Pathway
7.9K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.9K
MAPK Signaling Cascades
6.1K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.1K
